Hasan GÖZE

Dr. Hasan GÖZE

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in International Journal of Hematologic Oncology
Verified
Journal Article
Open access
OYOsman Yokus
Osman Yokus
CHCelalettin Herek
Celalettin Herek
TCTahir Alper Cinli
Tahir Alper Cinli
HGHasan GÖZE
Hasan GÖZE
ISIstemi Serin
Istemi Serin
Background: Recent studies have shown the increased risk of mortality in cases with acute leukemia and iron overload. We aimed to determine the status of iron overload in patients with acute leukem...

13 November 2020 in International Journal of Hematologic Oncology
Verified
Journal Article
Open access
ISIstemi Serin
Istemi Serin
ABAslıhan Bayir
Aslıhan Bayir
HGHasan GÖZE
Hasan GÖZE
OYOsman Yokus
Osman Yokus
Paroxysmal nocturnal hemoglobinuria (PNH) is defined by acquired intravascular hemolytic anemia, thrombosis and bone marrow failure with pancytopenia. Systemic lupus erythematosus (SLE) also appear...

1 August 2025 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
HGHasan GÖZE
Hasan GÖZE
EŞERDINÇ ŞENGÜLDÜR
ERDINÇ ŞENGÜLDÜR
Background: Timely and accurate diagnosis of pulmonary thromboembolism (PTE) in the emergency department (ED) is critical, yet remains challenging due to non-specific clinical features. Platelet indices have recently emerged as potential biomarkers, but their diagnostic utility is uncertain. Methods: In this retrospective single-center study, 1198 adult patients who underwent CT pulmonary angiography for suspected PTE in a tertiary ED were analyzed. Demographic characteristics and a comprehensive panel of hematological, biochemical, and coagulation parameters were compared between PTE (n = 126) and non-PTE (n = 1072) groups. Multivariate logistic regression and ROC curve analyses were performed to assess independent predictors and diagnostic performance. Results: Platelet indices including platelet count, mean platelet volume, platelet distribution width, plateletcrit, and derived ratios showed no significant differences between groups. However, PTE patients were older, more likely female, and exhibited significantly lower red blood cell count, hemoglobin, hematocrit, and higher neutrophil count (all P < .05). Multivariate analysis identified lower RBC and higher neutrophil count as independent predictors, while female sex was associated with decreased PTE risk. The model's discriminative ability was modest (AUC = 0.651). Conclusion: Platelet indices do not provide diagnostic value for PTE in the ED. Traditional demographic and hematological markers may aid risk stratification, but clinical integration remains essential. Prospective studies are needed to validate these findings and enhance diagnostic pathways.

26 June 2026 in Konuralp Tip Dergisi
Verified
Journal Article
Closed access
HGHasan GÖZE
Hasan GÖZE
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
Aim: Immune thrombocytopenia (ITP) is an autoimmune disorder with incompletely understood immunopathogenesis. This study aimed to evaluate the serum levels of monocyte-derived chemokines—CCL1, CCL3, CCL4, and CCL16—in newly diagnosed ITP patients, with a focus on their potential diagnostic and pathogenic relevance.Material and Methods: In a cross-sectional case-control design, 84 patients with primary ITP and 84 age- and sex-matched healthy controls were included. Serum chemokine concentrations were measured using ELISA.Results: CCL4 levels were significantly elevated in ITP patients (p < 0.001) and emerged as an independent predictor (OR = 1.158, p = 0.005). CCL1 levels were moderately increased (p = 0.038), and CCL3 reached statistical significance after outlier correction (p = 0.015). No significant differences were observed for CCL16. The logistic regression model yielded an overall classification accuracy of 82.1%, with ROC analysis supporting the potential diagnostic utility of CCL4.Conclusion: CCL4 may serve as a useful biomarker in the diagnosis and immunological assessment of ITP. Although CCL1 and CCL3 also showed some associations with disease status, further research is needed to clarify their clinical significance. Chemokine profiling may enhance the understanding of ITP’s immune mechanisms and support clinical monitoring strategies.

1 October 2026 in Experimental Biomedical Research
Verified
Journal Article
Open access
PDF file
HGHasan GÖZE
Hasan GÖZE
TETuna Eren Esen
Tuna Eren Esen
IYİsa Yalçınkaya
İsa Yalçınkaya
GBGökhan Burul
Gökhan Burul
TCTahir Alper Cinli
Tahir Alper Cinli
ISİstemi Serin
İstemi Serin
Aim: To determine whether next-generation sequencing (NGS) improves 2022 European LeukemiaNet (ELN) risk stratification by identifying myelodysplasia-related (MDS-related) mutations in acute myeloid leukemia (AML). Methods: We analyzed 111 consecutive adults with newly diagnosed non-promyelocytic acute myeloid leukemia (AML) who underwent diagnostic NGS with a myeloid gene panel. For each patient, an ELN 2022 risk category was assigned using four diagnostic modalities—metaphase karyotyping, fluorescence in situ hybridization (FISH), targeted molecular (PCR) testing, and NGS. A conventional category was defined as the most adverse assignment obtained from karyotyping, FISH, and PCR, whereas the NGS-inclusive category was defined as the most adverse assignment obtained when NGS was added to these modalities. The primary outcome was within-patient reclassification attributable to the incorporation of NGS. Reporting followed the STROBE guidelines. Results: The median age was 56 years, and 65.8% of patients were male. The most frequently mutated genes were FLT3 (25.2%), NPM1 (19.8%), TET2 (17.1%), TP53 (16.2%), and RUNX1 (16.2%); 38.7% of patients harbored at least one MDS-related mutation. Among the 110 patients with both classifications available, incorporation of NGS upgraded the ELN 2022 category in 33 patients (30.0%; 95% CI, 22.2–39.1)—29 from intermediate and 4 from favorable to adverse—with no downgrades. The proportion of patients classified as adverse risk more than doubled, from 30 (27.3%) to 63 (57.3%) (McNemar p < 0.001). Upgrades were driven predominantly by MDS-related mutations: 29 of 33 upgraded patients (87.9%) carried at least one such mutation, most commonly in ASXL1 (45.5%), RUNX1 (39.4%), SRSF2 (30.3%), or STAG2 (24.2%). Conclusions: Even among patients selected for NGS testing, an ELN 2022 category based on conventional cytogenetic and PCR testing alone was inaccurate, almost invariably too favorable, in approximately one in three patients, and no clinical feature reliably identified them. NGS is therefore indispensable for accurate risk stratification in AML.

25 November 2020 in Istanbul Medical Journal
Verified
Journal Article
Closed access
ISİstemi Serin
İstemi Serin
MDMehmet Hilmi Doğu
Mehmet Hilmi Doğu
HGHasan GÖZE
Hasan GÖZE
HMHarun Muğlu
Harun Muğlu
OYOsman Yokuş
Osman Yokuş